A post-incorporation study on the use of palivizumab in the Brazilian public health system
ABSTRACT Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in infants and children under five years of age. As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-ri...
Published in: | Revista do Instituto de Medicina Tropical de São Paulo |
---|---|
Main Authors: | , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Universidade de São Paulo (USP)
2021
|
Subjects: | |
Online Access: | https://doi.org/10.1590/s1678-9946202163005 https://doaj.org/article/cd3e6d35d5ff49a3ac09ea805b39e4d6 |
id |
ftdoajarticles:oai:doaj.org/article:cd3e6d35d5ff49a3ac09ea805b39e4d6 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:cd3e6d35d5ff49a3ac09ea805b39e4d6 2024-09-09T19:27:19+00:00 A post-incorporation study on the use of palivizumab in the Brazilian public health system Joanna d’Arc Lyra Batista Maria Angélica Pires Ferreira Cilene da Silva Xavier Ires Tarsila Alves de Souza Luciane Nascimento Cruz Carisi Anne Polanczyk 2021-01-01T00:00:00Z https://doi.org/10.1590/s1678-9946202163005 https://doaj.org/article/cd3e6d35d5ff49a3ac09ea805b39e4d6 EN eng Universidade de São Paulo (USP) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652021000100203&tlng=en https://doaj.org/toc/1678-9946 1678-9946 doi:10.1590/s1678-9946202163005 https://doaj.org/article/cd3e6d35d5ff49a3ac09ea805b39e4d6 Revista do Instituto de Medicina Tropical de São Paulo, Vol 63 (2021) Palivizumab Respiratory syncytial viruses Infant health Comparative effectiveness research Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2021 ftdoajarticles https://doi.org/10.1590/s1678-9946202163005 2024-08-05T17:49:30Z ABSTRACT Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in infants and children under five years of age. As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-risk cases during the RSV season. The present study aimed to evaluate the effectiveness of a public prophylaxis program with palivizumab on the incidence of hospitalizations for lower respiratory tract infections and RSV in children at high risk for severe RSV infections. A retrospective cohort study was carried out with preterm children or children under two years of age with chronic lung disease or hemodynamically significant congenital heart disease; the children were selected on the basis of their exposure status, which was defined as the prophylactic use of palivizumab during the RSV season. Children were enrolled retrospectively in two hospitals located in Southern Brazil, from May 2009 to August 2016. In a sample of 129 children, 69 (53.5%) received palivizumab and adherence to three or more doses was observed in 78%; 60 (46.5%) children did not receive palivizumab. PVZ prophylaxis was independently associated with a 66% reduction in hospitalizations for any cause (26/69 - 37.7%) in the PVZ group and 34/60 (56.7%) in the control group). A 52% reduction in hospitalizations due to lower respiratory tract infection was observed in the PVZ group (15/69 -21.7%) and 25/60 (41.7%) in the control group. These findings suggest that, for the group of studied patients, the adoption of an RSV prophylaxis scheme reached the same effectiveness as those described in previous clinical trials. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Revista do Instituto de Medicina Tropical de São Paulo 63 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Palivizumab Respiratory syncytial viruses Infant health Comparative effectiveness research Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
spellingShingle |
Palivizumab Respiratory syncytial viruses Infant health Comparative effectiveness research Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 Joanna d’Arc Lyra Batista Maria Angélica Pires Ferreira Cilene da Silva Xavier Ires Tarsila Alves de Souza Luciane Nascimento Cruz Carisi Anne Polanczyk A post-incorporation study on the use of palivizumab in the Brazilian public health system |
topic_facet |
Palivizumab Respiratory syncytial viruses Infant health Comparative effectiveness research Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
description |
ABSTRACT Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in infants and children under five years of age. As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-risk cases during the RSV season. The present study aimed to evaluate the effectiveness of a public prophylaxis program with palivizumab on the incidence of hospitalizations for lower respiratory tract infections and RSV in children at high risk for severe RSV infections. A retrospective cohort study was carried out with preterm children or children under two years of age with chronic lung disease or hemodynamically significant congenital heart disease; the children were selected on the basis of their exposure status, which was defined as the prophylactic use of palivizumab during the RSV season. Children were enrolled retrospectively in two hospitals located in Southern Brazil, from May 2009 to August 2016. In a sample of 129 children, 69 (53.5%) received palivizumab and adherence to three or more doses was observed in 78%; 60 (46.5%) children did not receive palivizumab. PVZ prophylaxis was independently associated with a 66% reduction in hospitalizations for any cause (26/69 - 37.7%) in the PVZ group and 34/60 (56.7%) in the control group). A 52% reduction in hospitalizations due to lower respiratory tract infection was observed in the PVZ group (15/69 -21.7%) and 25/60 (41.7%) in the control group. These findings suggest that, for the group of studied patients, the adoption of an RSV prophylaxis scheme reached the same effectiveness as those described in previous clinical trials. |
format |
Article in Journal/Newspaper |
author |
Joanna d’Arc Lyra Batista Maria Angélica Pires Ferreira Cilene da Silva Xavier Ires Tarsila Alves de Souza Luciane Nascimento Cruz Carisi Anne Polanczyk |
author_facet |
Joanna d’Arc Lyra Batista Maria Angélica Pires Ferreira Cilene da Silva Xavier Ires Tarsila Alves de Souza Luciane Nascimento Cruz Carisi Anne Polanczyk |
author_sort |
Joanna d’Arc Lyra Batista |
title |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_short |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_full |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_fullStr |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_full_unstemmed |
A post-incorporation study on the use of palivizumab in the Brazilian public health system |
title_sort |
post-incorporation study on the use of palivizumab in the brazilian public health system |
publisher |
Universidade de São Paulo (USP) |
publishDate |
2021 |
url |
https://doi.org/10.1590/s1678-9946202163005 https://doaj.org/article/cd3e6d35d5ff49a3ac09ea805b39e4d6 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Revista do Instituto de Medicina Tropical de São Paulo, Vol 63 (2021) |
op_relation |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652021000100203&tlng=en https://doaj.org/toc/1678-9946 1678-9946 doi:10.1590/s1678-9946202163005 https://doaj.org/article/cd3e6d35d5ff49a3ac09ea805b39e4d6 |
op_doi |
https://doi.org/10.1590/s1678-9946202163005 |
container_title |
Revista do Instituto de Medicina Tropical de São Paulo |
container_volume |
63 |
_version_ |
1809896767260459008 |